Dismal outcome of t-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry
Dismal outcome of t-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry
复制标题
DOI：
10.1002/hon.2144
复制
发表时间：
2015-09-01
影响因子：
3.3
通讯作者：
Luminari, Stefano
中科院分区：
文献类型：
--
作者：
Biasoli, Irene;Cesaretti, Marina;Luminari, Stefano
我们进行了一项基于人群的研究，以确定 T 细胞淋巴瘤 (TCL) 患者接受全身一线治疗的结果。 1997 年至 2010 年间，摩德纳省一线全身治疗失败的所有 TCL 患者均通过摩德纳癌症登记处确定。总共对 53 名患者进行了分析。关于失败的类型，18名患者复发。 35 例在第一次治疗期间出现进展。在复发患者中，从首次治疗后出现反应到复发的中位时间为 6.2 个月（范围 1.87-102）。共有 18 名患者 (34%) 在接受挽救治疗前死亡，21 名患者接受含铂或吉西他滨的治疗方案（7 名患者接受自体干细胞移植 (ASCT)），12 名患者接受其他 CT 治疗方案； 2 人接受放射治疗 (RT)。复发后中位生存期 (SAR) 为 2.5 个月。对失败后的存活患者进行中位随访 35 个月（范围 8-111 个月）后，44 名患者死亡，除一名患者外，所有患者 (98%) 的死亡原因被发现是淋巴瘤进展。 SAR 中位数为 2.5 个月。 3年SAR为19%。对 SAR 进行单变量和多变量 Cox 回归分析。在多变量分析中，体能状态和失败类型与复发后较高的死亡风险相关。一线治疗失败的 TCL 患者预后较差。只有少数可以接受 ASCT 的病例有希望获得长期缓解的机会。对于需要二线治疗的患者来说，迫切需要新的药物。 (C) 版权所有 2014 John Wiley & Sons, Ltd.
We conducted a population-based study to establish the outcome of T-cell lymphoma (TCL) patients Ming systemic first-line therapy. All TCL patients failing first-line systemic therapy in the province of Modena were identified from Modena Cancer Registry between 1997 and 2010. A total of 53 patients were analysed. Regarding the type of failure, 18 patients relapsed. and 35 progressed during first treatment. Among relapsed patients, the median time from date of response to relapse after first treatment was 6.2 months (range 1.87-102). A total of 18 patients (34%) died before receiving salvage treatment, 21 received platinum or gemcitabine-containing regimens (7 addressed to autologous stem cell transplant (ASCT)), 12 other CT regimens; 2 received radiotherapy (RT). The median survival after relapse (SAR) was 2.5 months. After a median follow-up for living patients after failure of 35 months (range 8-111 months), 44 patients died, and the cause of death was found to be lymphoma progression in all (98%) but one of them. The median SAR was 2.5 months. The 3-year SAR was 19%. Univariate and multivariate Cox regression analyses for SAR were performed. In multivariate analysis, performance status and type of failure were associated with a higher risk of death after relapse. The outcome of TCL patients failing first-line therapy is poor. Only a few cases that could receive ASCT had promising chances of long remission. There is urgent need for novel agents for patients requiring second-line treatment. (C) Copyright 2014 John Wiley & Sons, Ltd.